Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CCEL

CCEL - CRYO-CELL International, Inc. Stock Price, Fair Value and News

8.25USD+0.27 (+3.38%)Market Closed

Market Summary

CCEL
USD8.25+0.27
Market Closed
3.38%

CCEL Stock Price

View Fullscreen

CCEL RSI Chart

CCEL Valuation

Market Cap

68.3M

Price/Earnings (Trailing)

-7.02

Price/Sales (Trailing)

2.18

EV/EBITDA

-5.73

Price/Free Cashflow

-32.1K

CCEL Price/Sales (Trailing)

CCEL Profitability

EBT Margin

-43.94%

Return on Equity

94.14%

Return on Assets

-15.77%

Free Cashflow Yield

0%

CCEL Fundamentals

CCEL Revenue

Revenue (TTM)

31.4M

Rev. Growth (Yr)

0.36%

Rev. Growth (Qtr)

-0.31%

CCEL Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

-27.46%

Earnings Growth (Qtr)

104.97%

Breaking Down CCEL Revenue

Last 7 days

-0.7%

Last 30 days

-5.7%

Last 90 days

51.1%

Trailing 12 Months

48.4%

How does CCEL drawdown profile look like?

CCEL Financial Health

Current Ratio

0.49

Debt/Equity

-0.14

Debt/Cashflow

4.86

CCEL Investor Care

Dividend Yield

12.48%

Dividend/Share (TTM)

0.9

Buy Backs (1Y)

2.40%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202431.4M000
202330.9M31.0M31.2M31.3M
202229.3M29.7M29.9M30.3M
202130.4M29.7M29.1M28.9M
202031.9M31.7M31.6M31.1M
201930.5M32.1M32.4M31.8M
201825.8M26.1M27.1M29.2M
201723.8M24.2M24.8M25.4M
201621.4M22.2M23.1M23.1M
201519.6M19.8M20.3M21.1M
201419.7M19.7M19.9M20.1M
201318.4M18.8M19.1M19.0M
201217.6M17.4M17.6M18.0M
201117.8M17.8M17.9M17.9M
201000017.8M

Tracking the Latest Insider Buys and Sells of CRYO-CELL International, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 18, 2022
portnoy david
bought
2,616
4.89985
534
chairman, co-ceo
Nov 17, 2022
portnoy david
bought
2,528
4.9
516
chairman, co-ceo
Nov 15, 2022
portnoy david
bought
45,556
4.8
9,491
chairman, co-ceo
Nov 15, 2022
portnoy david
sold
-76,860
4.80375
-16,000
chairman, co-ceo
Nov 14, 2022
portnoy david
bought
48,000
4.8
10,000
chairman, co-ceo
Nov 14, 2022
portnoy david
sold
-48,000
4.8
-10,000
chairman, co-ceo
Nov 11, 2022
portnoy david
bought
28,710
4.785
6,000
chairman, co-ceo
Nov 11, 2022
portnoy david
sold
-45,471
4.78896
-9,495
chairman, co-ceo
Nov 10, 2022
portnoy david
sold
-
-
-9,122
chairman, co-ceo
Nov 10, 2022
portnoy david
sold
-
-
-9,974
chairman, co-ceo

1–10 of 50

Which funds bought or sold CCEL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 03, 2024
HAMILTON LANE ADVISORS LLC
unchanged
-
1,401,290
6,113,230
2.12%
May 15, 2024
Royal Bank of Canada
reduced
-28.16
-
1,000
-%
May 15, 2024
MORGAN STANLEY
unchanged
-
1,026
4,476
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-12.00
-
-%
May 14, 2024
NORTHERN TRUST CORP
reduced
-11.11
23,174
174,400
-%
May 14, 2024
Cerity Partners LLC
unchanged
-
33,453
145,940
-%
May 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
added
2.27
39,403
159,934
-%
May 13, 2024
UBS Group AG
sold off
-100
-4,261
-
-%
May 13, 2024
SFI Advisors, LLC
unchanged
-
282,663
1,233,140
0.97%
May 10, 2024
OSAIC HOLDINGS, INC.
unchanged
-
4,275
18,650
-%

1–10 of 18

Are Funds Buying or Selling CCEL?

Are funds buying CCEL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CCEL
No. of Funds

Unveiling CRYO-CELL International, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
iszo capital lp
2.3%
195,031
SC 13G/A
Feb 14, 2022
iszo capital lp
5.7%
482,931
SC 13G/A

Recent SEC filings of CRYO-CELL International, Inc.

View All Filings
Date Filed Form Type Document
Apr 15, 2024
10-Q
Quarterly Report
Mar 26, 2024
8-K
Current Report

Peers (Alternatives to CRYO-CELL International, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
453.8B
379.5B
-3.65% 0.77%
29.54
1.2
12.96% -25.81%
95.5B
206.0B
-3.75% 23.43%
24.77
0.46
12.55% -43.95%
89.3B
66.7B
7.45% 22.04%
16.32
1.34
9.59% -4.59%
75.3B
360.9B
6.23% -16.98%
10.28
0.21
9.07% 78.83%
36.1B
155.5B
-12.24% -2.53%
13.21
0.23
6.34% 84.42%
12.6B
14.7B
4.84% 32.82%
15.41
0.86
7.99% 19.23%
12.5B
12.3B
4.47% 45.25%
15.34
1.01
5.77% 58.74%
MID-CAP
8.2B
2.3B
-4.83% -0.18%
28.88
3.57
5.96% 18.29%
6.3B
3.0B
-5.43% -3.06%
-556.78
2.1
10.92% -104.06%
2.2B
1.5B
0.05% 19.70%
35.94
1.54
19.34% 40.15%
2.0B
3.5B
-9.25% -51.02%
14.14
0.58
-27.67% -62.40%
SMALL-CAP
1.9B
1.1B
7.13% 25.50%
29.53
1.78
11.45% 30.74%
1.3B
3.0B
-3.72% 59.10%
-7.46
0.43
4.98% 4.88%
59.5M
-
13.00% -23.39%
-3.94
-
- -1.05%
20.7M
21.6M
-6.30% 25.29%
40.75
0.96
9.04% -57.88%

CRYO-CELL International, Inc. News

Latest updates
Defense World03 Jun 202408:40 am
Stock Traders Daily26 May 202402:04 pm
Business Observer13 years ago

CRYO-CELL International, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-0.3%7,8527,8777,8707,7737,8247,7647,6817,6337,2597,3157,5047,2056,8617,5418,1147,8727,6217,9708,2238,1287,495
Costs and Expenses-70.8%7,03124,0536,7096,7456,1417,3596,7276,4395,7888,1245,9075,2105,6255,3605,6346,1206,3726,2516,2307,6316,641
  S&GA Expenses-19.5%4,3405,3933,8054,0393,8794,6883,6033,9133,3764,5353,4943,1483,4333,4903,3763,5593,8703,9423,5573,6483,745
  R&D Expenses13.3%50344434430579.0076.0080.0081.0014730.0010.003.006.007.001.0010.006.0017.002.005.006.00
EBITDA Margin-7.9%-0.38*-0.35*0.20*0.19*0.20*0.20*0.13*0.15*0.18*0.17*0.26*0.24*0.22*--------
Interest Expenses251.7%256-169470470466574365277306421336341280475339365365458414424407
Income Taxes105.0%238-4,803387125448-215174265324-60640547125963115238025244649951.00105
Earnings Before Taxes105.0%795-15,9931,0683461,2156236419001,156-1,2431,2611,6419521,8319361,3339391,2911,615105381
EBT Margin-3.1%-0.44*-0.43*0.10*0.09*0.11*0.11*0.05*0.07*0.10*0.09*0.20*0.18*0.17*--------
Net Income105.0%556-11,190681221767838467635832-6378561,1716941,2007849536878451,11654.00276
Net Income Margin-2.1%-0.31*-0.30*0.08*0.07*0.09*0.09*0.04*0.06*0.08*0.07*0.13*0.13*0.12*--------
Free Cashflow-150.0%-8141,629-1,3485321,2682,455-8,5491,6408591,3875281,5272,650--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets0.8%61,71161,22169,79668,75866,13464,88866,76555,39554,80860,66259,42458,318105,26446,20044,44044,84144,73042,88641,82840,88943,342
  Current Assets0.0%9,4529,4539,93610,31310,6379,61011,14110,3059,71715,78314,92114,78318,69618,55616,76417,28016,89515,38815,92015,00230,376
    Cash Equivalents-39.1%2474065841,1241,3731,7042,9252,8042,1458,2637,7017,94811,27810,3618,1088,4208,4166,5417,3396,4697,076
  Inventory-1.8%7557691,0638799008519198739289218348908689271,2031,0541,1031,0851,0321,04616,133
  Net PPE2.9%21,60520,99718,83617,09814,42713,60315,1794,0283,8053,2303,0281,5531,5971,6411,6641,7391,7751,8461,7691,7481,465
  Goodwill0%1,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,941
Liabilities-0.3%72,04972,25269,81369,61666,82266,41269,15150,98850,55756,47854,62554,315106,96048,86548,47649,82350,73149,83948,79148,98351,577
  Current Liabilities-7.2%19,37020,86418,56319,70818,91219,48123,62415,71116,38721,07419,85820,12029,84516,41514,42815,09916,07015,42914,26713,61115,279
  Long Term Debt--------------------1,4251,425
    LT Debt, Non Current--------------------1,4251,425
Shareholder's Equity6.3%-10,338-11,031---687-1,524-4,4074,2514,1844,7994,003---------
  Retained Earnings1.8%-30,602-31,159-19,969-20,649-20,870-21,637-22,475-15,269-15,904-16,736-16,099-16,955-18,126-18,819-20,019-20,804-21,757-22,444-23,289-24,405-24,459
  Additional Paid-In Capital0.7%43,71843,41143,23643,06742,91142,59742,44641,76841,65041,58741,31541,37736,85836,58236,41036,24836,18435,91935,76135,74735,660
Shares Outstanding-0.4%8,2558,2878,2878,2878,4678,5018,4498,4798,5278,5528,4527,7607,571--------
Float----27,010---35,449---47,607---29,618---30,375-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-110.7%-3563,3441,9421,9891,6442,4302,6891,9471,5071,6672,0591,5372,6622,9772,0528222,6161,1242,7895281,854
  Share Based Compensation75.7%30717517215631315116111732.0068.0081.0068.0085.0017116264.0022415814.0087.00139
Cashflow From Investing82.8%-341-1,981-3,386-1,574-1,2011,916-11,22684.00-6,053-290-1,531-4,966-16152.00356-43.27-6.96-154-98.47-359-49.08
Cashflow From Financing135.0%539-1,540904-663-772-5,5668,657-1,371-1,571-814-775100-1,583-775-2,720-775-734-1,767-1,820-775-769
  Buy Backs-170-8.00548243127267596829249-----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CCEL Income Statement

2024-02-29
Consolidated Statements of Income - USD ($)
3 Months Ended
Feb. 29, 2024
Feb. 28, 2023
Revenue$ 7,852,235$ 7,824,415
Costs and Expenses:  
Cost of sales2,160,4682,067,364
Selling, general and administrative expenses4,339,6453,878,903
Change in fair value of contingent consideration(5,176)(164,701)
Research, development and related engineering502,88978,834
Depreciation and amortization33,186280,844
Total costs and expenses7,031,0126,141,244
Operating Income821,2231,683,171
Other Income (Expense):  
Gains (losses) on marketable securities274,971(3,681)
Loss on interest rate swap(45,288)0
Other income631,268
Interest expense(256,459)(466,231)
Total other income (expense)(26,713)(468,644)
Income before income tax expense794,5101,214,527
Income tax expense(238,269)(447,715)
Net income$ 556,241$ 766,812
Net income per common share - basic$ 0.07$ 0.09
Weighted average common shares outstanding - basic8,277,8448,467,074
Net income per common share - diluted$ 0.07$ 0.09
Weighted average common shares outstanding - diluted8,325,0278,474,737
Processing and Storage Fees [Member]  
Revenue$ 7,805,522$ 7,561,518
Public Banking Revenue [Member]  
Revenue43,713230,697
Product Revenue [Member]  
Revenue$ 3,000$ 32,200

CCEL Balance Sheet

2024-02-29
Consolidated Balance Sheets - USD ($)
Feb. 29, 2024
Nov. 30, 2023
Current Assets  
Cash and cash equivalents$ 247,112$ 406,067
Marketable securities732,481574,183
Accounts receivable (net of allowance for doubtful accounts of $3,939,638 and $3,822,300, respectively)6,726,8936,576,240
Prepaid expenses535,295615,407
Inventory, current portion755,160768,877
Swap contract76,825122,113
Other current assets378,310389,950
Total current assets9,452,0769,452,837
Property and Equipment-net21,605,27320,996,883
Other Assets  
Intangible assets, net972,154989,121
Inventory, net of current portion5,223,9805,260,119
Goodwill1,941,4111,941,411
Deferred tax assets20,492,74920,492,749
Operating lease right-of-use asset958,0221,033,157
Deposits and other assets, net757,109746,493
Total other assets30,653,42530,771,050
Total assets61,710,77461,220,770
Current Liabilities  
Accounts payable2,996,6583,174,584
Accrued expenses3,916,8985,170,809
Note payable168,623165,641
Line of credit1,972,7281,222,728
Current portion of operating lease liability253,981225,686
Duke license agreement liability666,6671,200,000
Deferred revenue9,394,8219,704,553
Total current liabilities19,370,37620,864,001
Other Liabilities  
Deferred revenue, net of current portion42,603,66141,186,800
Contingent consideration39,05044,226
Note payable, net of current portion and debt issuance costs8,391,7388,430,037
Operating lease long-term liability768,961851,938
Long-term liability - revenue sharing agreements875,000875,000
Total other liabilities52,678,41051,388,001
Total liabilities72,048,78672,252,002
Commitments and contingencies (Note 9)00
Stockholders' Deficit  
Preferred stock00
Common stock ($.01 par value, 20,000,000 authorized; 14,849,246 issued and 8,254,977 outstanding as of February 29, 2024 and 14,849,246 issued and 8,286,785 outstanding as of November 30, 2023)148,492148,492
Additional paid-in capital43,718,49843,411,143
Treasury stock, at cost(23,602,061)(23,431,685)
Accumulated deficit(30,602,941)(31,159,182)
Total stockholders' deficit(10,338,012)(11,031,232)
Total liabilities and stockholders' equity61,710,77461,220,770
Series A Junior Participating Preferred Stock [Member]  
Stockholders' Deficit  
Preferred stock00
Tianhe Stem Cell Biotechnologies Inc [Member]  
Other Assets  
Investment$ 308,000$ 308,000
CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
 CEO
 WEBSITEcryo-cell.com
 INDUSTRYHealthcare Plans
 EMPLOYEES80

CRYO-CELL International, Inc. Frequently Asked Questions


What is the ticker symbol for CRYO-CELL International, Inc.? What does CCEL stand for in stocks?

CCEL is the stock ticker symbol of CRYO-CELL International, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CRYO-CELL International, Inc. (CCEL)?

As of Wed Jun 12 2024, market cap of CRYO-CELL International, Inc. is 68.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCEL stock?

You can check CCEL's fair value in chart for subscribers.

What is the fair value of CCEL stock?

You can check CCEL's fair value in chart for subscribers. The fair value of CRYO-CELL International, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CRYO-CELL International, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CCEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CRYO-CELL International, Inc. a good stock to buy?

The fair value guage provides a quick view whether CCEL is over valued or under valued. Whether CRYO-CELL International, Inc. is cheap or expensive depends on the assumptions which impact CRYO-CELL International, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCEL.

What is CRYO-CELL International, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, CCEL's PE ratio (Price to Earnings) is -7.02 and Price to Sales (PS) ratio is 2.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CRYO-CELL International, Inc.'s stock?

In the past 10 years, CRYO-CELL International, Inc. has provided 0.129 (multiply by 100 for percentage) rate of return.